Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma

Abstract Lenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrospective study evaluated outcomes and safety of VRd and KRd. Primary endpoint was progression-free survival (PFS). Of 389 patients with newly d...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, Amanda Ciardiello, Benjamin Diamond, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Kylee Maclachlan, Dhwani Patel, Oscar B. Lahoud, Heather J. Landau, David J. Chung, Gunjan L. Shah, Michael Scordo, Sergio A. Giralt, Alexander Lesokhin, Saad Z. Usmani, Ola Landgren, Neha Korde
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Publishing Group 2023-07-01
Colecção:	Blood Cancer Journal
Acesso em linha:	https://doi.org/10.1038/s41408-023-00882-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!